Clareo Health | iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)
Able to provide sufficient and qualified blood samples for study tests.
No prior or undergoing cancer treatment (local or systematic) with either of the following:
A. Pathologically confirmed cancer diagnosis within 42 days prior to the study blood draw.
B. High suspicious for cancer diagnosis by radiological or other routine clinical assessments, with confirmed cancer diagnosis through biopsy or surgical resection within 42 days after study blood draw.
Able to provide a written informed consent.
Able to provide sufficient and qualified blood samples for study tests.
Have either of the following:
A. Pathological confirmed diagnosis of benign diseases within 90 days prior to the study blood draw, with no prior treatment such as surgical resection.
B. High suspicious for benign diseases diagnosis by radiological or other routine clinical assessments, with confirmed benign diseases diagnosis within 42 days after study blood draw.
You may not be if
Insufficient qualified blood sample for study test.
During pregnancy or lactation.
Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
Recipient of blood transfusion within 30 days prior to study blood draw.
With other known malignant tumors or multiple primary tumors.
Insufficient qualified blood sample for study test.
During pregnancy or lactation.
Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
Recipient of blood transfusion within 30 days prior to study blood draw.
Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer
